R 715 (trifluoroacetate salt)

R 715 is a bradykinin B₁ receptor antagonist.¹ It inhibits contractions induced by bradykinin in isolated human umbilical cords, which express bradykinin B₁ receptors (pA₂ = 8.49). R 715 (200, 400, and 600 µg/kg) decreases the latency to tail withdrawal in the tail-flick test in a mouse model of diabetic neuropat induced by streptozotocin .² It reduces the incidence of hind limb weakness and paralysis, improves symmetrical gait, as well as decreases spinal inflammatory foci numbers, neuron demyelination, and lesion monocyte invasion, in a myelin oligodendrocyte glycoprotein (MOG) (35-55) (MOG_35-55) antigen peptide-induced mouse model of experimental autoimmune encephalomyelitis (EAE) when administered at a dose of 1 mg/kg per day.³ R 715 (0.01 nmol/animal, i.c.v.) reduces mean arterial blood pressure and increases heart rate in spontaneously pertensive rats.⁴